675:
ratio to receive doses of either 150 mg every 4 weeks, 300 mg every 4 weeks, or 300 mg every 2 weeks. Participants on the medication had a statistically significant reduction in hereditary angioedema attack rates per month. Participants that took lanadelumab every 2 weeks had 83% less moderate to severe attacks. The study results proved that all three dosing regimens for lanadelumab were more effective than placebo.
2884:
1203:
1124:
674:
There were 125 participants studied over a 26-week period in the randomized, double-blind, parallel-group, placebo-controlled trial. Participants were randomized to receive either lanadelumab treatment or placebo in a 1:2 ratio. Subjects randomized to receive lanadelumab were further randomized 1:1:1
1254:
618:
results in increased levels of kallikrein and subsequent proteolysis of kininogen. The proteolysis of the kininogen forces an upscaled production of bradykinin and kininogen within the patient. Increased bradykinin levels cause
1250:
226:
1530:
667:
designations by the Food and Drug
Administration. The phase 3 HELP study evaluated efficacy and safety of lanadelumab. This drug was produced by Dyax Corp and currently under development by
1829:
1109:
1188:
181:
1611:
806:
1228:
986:
93:
547:
In a phase III randomized controlled trial, which examined the efficacy and safety of lanadelumab in preventing hereditary angioedema attacks, the most common
1509:
for "Double-Blind, Multiple
Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema (HAE) Subjects" at
1822:
1069:
721:
741:
36:
1604:
1522:
523:
approved the use of lanadelumab in August 2018, for people that are 12 years and older and have either type I or type II hereditary angioedema.
1815:
1472:
1382:
1011:
909:
1027:
2838:
1251:"U.S. FDA Approves Takeda's Takhzyro (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older"
1101:
1597:
836:
1360:
1177:
559:
473:. Lanadelumab, was approved in the United States as the first monoclonal antibody indicated for prophylactic treatment to prevent
798:
771:
651:. Lanadelumab's approval in the United States was spearheaded by the data presented in the phase 1b, multicenter, double blind,
211:
111:
700:
2904:
2810:
1571:
1291:
668:
1409:
2874:
1523:"Dyax Corp. Receives FDA Breakthrough Therapy Designation for DX-2930 for Prevention of Attacks of Hereditary Angioedema"
1315:"Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial"
2820:
1224:
1220:
1183:
1105:
1036:
520:
348:
722:
https://www.tga.gov.au/resources/prescription-medicines-registrations/takhzyro-takeda-pharmaceuticals-australia-pty-ltd
130:
2855:
493:
1659:
1770:
1288:"Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE"
2404:
1050:
1054:
1765:
1755:
652:
2843:
733:
485:
167:
937:
174:
1491:
for "A Single
Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects" at
614:, which is an enzyme that regulates the activity of the kallikrein-kinin cascade. Poor regulation of the
2909:
1916:
1838:
1686:
1466:
1376:
1005:
903:
644:
624:
536:
478:
474:
470:
1150:
2120:
660:
1737:
1313:
Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, et al. (November 2018).
1024:
858:
Kenniston JA, Faucette RR, Martik D, Comeau SR, Lindberg AP, Kopacz KJ, et al. (August 2014).
458:
292:
46:
29:
764:"Takhzyro 300 mg solution for injection in pre-filled syringe - Patient Information Leaflet (PIL)"
2305:
2264:
2104:
1896:
1650:
1510:
1492:
1352:
978:
141:
1055:"International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114"
936:
Banerji A, Busse P, Shennak M, Lumry W, Davis-Lorton M, Wedner HJ, et al. (February 2017).
1431:
Chyung Y, Vince B, Iarrobino R, Sexton D, Kenniston J, Faucette R, et al. (October 2014).
2196:
1866:
1807:
1454:
1344:
970:
891:
268:
255:
238:
75:
828:
301:
2186:
2176:
1742:
1444:
1334:
1326:
1314:
960:
952:
881:
871:
393:
357:
2888:
2604:
2380:
1031:
656:
627:, and the succeeding angioedema and pain associated with hereditary angioedema attacks.
103:
2849:
1339:
886:
859:
636:
2898:
2759:
2560:
2505:
2430:
2390:
2310:
2204:
1850:
1842:
1760:
1711:
1670:
1665:
1207:
1128:
763:
548:
1356:
982:
860:"Inhibition of plasma kallikrein by a highly specific active site blocking antibody"
799:"Takhzyro- lanadelumab-flyo solution Takhzyro- lanadelumab-flyo injection, solution"
2749:
2734:
2714:
2704:
2683:
2599:
2540:
2525:
2495:
2475:
2470:
2445:
2425:
2420:
2415:
2365:
2355:
2345:
2295:
2290:
2285:
2214:
2099:
2083:
1986:
1976:
1971:
1946:
1886:
1746:
1706:
1701:
1692:
1655:
1645:
1631:
1621:
1589:
692:
620:
615:
611:
604:
194:
189:
1563:
1505:
1487:
1287:
555:
Injection site reactions, such as pain, redness, and bruising in 42.9% of patients
2815:
2805:
2744:
2729:
2719:
2709:
2688:
2673:
2658:
2653:
2648:
2623:
2576:
2555:
2550:
2545:
2535:
2530:
2515:
2490:
2480:
2460:
2440:
2435:
2400:
2395:
2385:
2375:
2370:
2340:
2330:
2300:
2254:
2249:
2239:
2224:
2209:
2181:
2166:
2151:
2146:
2141:
2109:
2052:
2047:
2037:
2017:
1996:
1991:
1881:
1716:
664:
1449:
1432:
2775:
2754:
2739:
2724:
2668:
2663:
2643:
2638:
2609:
2583:
2520:
2500:
2485:
2465:
2455:
2410:
2360:
2350:
2325:
2320:
2315:
2280:
2275:
2244:
2229:
2171:
2161:
2156:
2136:
2073:
2068:
2057:
2027:
2022:
1966:
1941:
1926:
1911:
1906:
1876:
648:
600:
588:
466:
462:
432:
332:
63:
2678:
2510:
2335:
2234:
2219:
2078:
2042:
2032:
2006:
2001:
1981:
1956:
1951:
1936:
1931:
1901:
1871:
1780:
1775:
1721:
1640:
1405:
1330:
1025:
Statement On A Nonproprietary Name
Adopted By The USAN Council - Lanadelumab
876:
640:
596:
532:
509:
97:
22:
1458:
1348:
974:
895:
610:
People have hereditary angioedema because of a deficiency or dysfunctional
956:
2088:
2011:
1921:
1891:
592:
569:
513:
497:
312:
125:
655:, multi-ascending-dose trial. Through this trial, lanadelumab was given
321:
2565:
2450:
1675:
965:
505:
58:
639:
Lanadelumab was well tolerated and was reported to reduce cleavage of
2790:
489:
938:"Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis"
377:
1796:
51:
1206:
This article incorporates text from this source, which is in the
1127:
This article incorporates text from this source, which is in the
647:
and decrease the number of participants experiencing attacks of
501:
368:
274:
249:
1811:
1593:
481:
prevention made by using cells within a lab, not human plasma.
262:
120:
587:
Lanadelumab works by binding to an enzyme within the plasma,
1433:"A phase 1 study investigating DX-2930 in healthy subjects"
220:
152:
1146:
1178:"FDA approves new treatment for rare hereditary disease"
1102:"FDA approves new treatment for rare hereditary disease"
233:
2872:
793:
791:
789:
2798:
2788:
2768:
2697:
2631:
2622:
2591:
2263:
2195:
2129:
1858:
1849:
1789:
1735:
1684:
1629:
431:
392:
387:
367:
347:
331:
311:
291:
286:
210:
205:
180:
166:
140:
110:
92:
84:
74:
69:
57:
45:
35:
28:
1172:
1170:
1168:
484:Common side effects include pain associated with
477:attacks. Lanadelumab is the first treatment for
300:
1823:
1605:
693:"Lanadelumab (Takhzyro) Use During Pregnancy"
8:
129:
21:
591:, to inhibit its activity. Kallikrein is a
575:Injection site bruising in 7.1% of patients
2795:
2628:
1855:
1830:
1816:
1808:
1612:
1598:
1590:
1437:Annals of Allergy, Asthma & Immunology
1253:(Press release). Takeda. 4 February 2023.
1448:
1338:
964:
885:
875:
465:(pKal) in order to promote prevention of
356:
2879:
684:
461:(class IgG1 kappa) that targets plasma
320:
1464:
1374:
1231:from the original on 30 September 2022
1003:
901:
599:, subsequently creating kininogen and
551:noted in patients being treated were:
20:
1558:
1556:
1554:
1552:
1550:
1548:
1400:
1398:
1396:
1394:
1392:
1282:
1280:
1278:
1276:
1274:
1272:
1141:
1139:
1137:
1096:
1094:
1092:
1090:
531:In the United States, lanadelumab is
102:
7:
1412:from the original on 31 October 2021
1257:from the original on 6 February 2023
1191:from the original on 7 February 2023
1187:(Press release). 30 September 2021.
1112:from the original on 19 January 2021
992:from the original on 31 October 2021
931:
929:
927:
925:
923:
921:
919:
839:from the original on 19 October 2021
809:from the original on 20 January 2022
703:from the original on 20 October 2020
193:
945:The New England Journal of Medicine
864:The Journal of Biological Chemistry
643:in the plasma of participants with
376:
1574:from the original on 25 March 2017
1570:. Springer Nature Switzerland AG.
1533:from the original on 25 March 2017
1471:: CS1 maint: overridden setting (
1381:: CS1 maint: overridden setting (
1363:from the original on 7 August 2020
1294:from the original on 19 April 2021
1153:from the original on 3 August 2021
1075:from the original on 7 August 2020
1010:: CS1 maint: overridden setting (
908:: CS1 maint: overridden setting (
774:from the original on 19 April 2021
14:
1221:"Drug Trials Snapshots: Takhzyro"
560:upper respiratory tract infection
2882:
1406:"Clinical Pharmacology Database"
1201:
1122:
744:from the original on 30 May 2022
410:
404:
734:"Takhzyro Product information"
422:
416:
398:
1:
578:Dizziness in 6.0% of patients
565:Headache in 20.2% of patients
1620:Other hematological agents (
1225:Food and Drug Administration
1184:Food and Drug Administration
1106:Food and Drug Administration
1037:American Medical Association
521:Food and Drug Administration
453:, sold under the brand name
494:upper respiratory infection
2926:
1771:Lovotibeglogene autotemcel
1450:10.1016/j.anai.2014.05.028
388:Chemical and physical data
2833:
1051:World Health Organization
833:European Medicines Agency
595:that functions to cleave
1766:Exagamglogene autotemcel
1756:Betibeglogene autotemcel
1227:(FDA). 9 February 2019.
486:injection site reactions
1331:10.1001/jama.2018.16773
877:10.1074/jbc.M114.569061
535:for the prophylaxis of
1564:"Lanadelumab - Takeda"
1503:Clinical trial number
1485:Clinical trial number
2905:Monoclonal antibodies
1917:Camidanlumab tesirine
1839:Monoclonal antibodies
1108:. 30 September 2021.
957:10.1056/NEJMoa1605767
699:. 19 September 2018.
645:hereditary angioedema
625:vascular permeability
537:hereditary angioedema
479:hereditary angioedema
475:hereditary angioedema
471:hereditary angioedema
2592:Chimeric + humanized
2121:Nivolumab/relatlimab
1527:www.businesswire.com
1062:WHO Drug Information
1030:2 April 2016 at the
805:. 17 February 2022.
661:breakthrough therapy
562:in 23.8% of patients
1738:sickle cell disease
1660:+desoxyribonuclease
870:(34): 23596–23608.
835:. 17 October 2018.
583:Mechanism of action
459:monoclonal antibody
258:(Prescription only)
229:(Prescription only)
30:Monoclonal antibody
25:
16:Monoclonal antibody
2860:Never to phase III
2306:Certolizumab pegol
2273:Immunosuppressive:
1651:Desoxyribonuclease
1511:ClinicalTrials.gov
1493:ClinicalTrials.gov
1147:"www.takhzyro.com"
653:placebo controlled
572:in 95% of patients
2870:
2869:
2829:
2828:
2784:
2783:
2618:
2617:
2573:Immune activation
2065:Immune activation
1867:Immunosuppression
1805:
1804:
1325:(20): 2108–2121.
740:. 25 April 2012.
488:, injection site
448:
447:
278:
266:
253:
236:
224:
156:
123:
2917:
2887:
2886:
2885:
2878:
2796:
2629:
2187:Zolimomab aritox
2177:Telimomab aritox
1856:
1832:
1825:
1818:
1809:
1743:beta thalassemia
1614:
1607:
1600:
1591:
1584:
1583:
1581:
1579:
1560:
1543:
1542:
1540:
1538:
1519:
1513:
1501:
1495:
1483:
1477:
1476:
1470:
1462:
1452:
1428:
1422:
1421:
1419:
1417:
1402:
1387:
1386:
1380:
1372:
1370:
1368:
1342:
1310:
1304:
1303:
1301:
1299:
1284:
1267:
1266:
1264:
1262:
1247:
1241:
1240:
1238:
1236:
1217:
1211:
1205:
1204:
1200:
1198:
1196:
1174:
1163:
1162:
1160:
1158:
1143:
1132:
1126:
1125:
1121:
1119:
1117:
1098:
1085:
1084:
1082:
1080:
1074:
1059:
1047:
1041:
1022:
1016:
1015:
1009:
1001:
999:
997:
991:
968:
942:
933:
914:
913:
907:
899:
889:
879:
855:
849:
848:
846:
844:
825:
819:
818:
816:
814:
795:
784:
783:
781:
779:
760:
754:
753:
751:
749:
730:
724:
719:
713:
712:
710:
708:
689:
443:
441:
424:
418:
412:
406:
400:
380:
360:
324:
304:
276:
273:
264:
261:
251:
248:
244:
235:
232:
222:
219:
197:
154:
151:
133:
122:
119:
106:
88:lanadelumab-flyo
26:
24:
2925:
2924:
2920:
2919:
2918:
2916:
2915:
2914:
2895:
2894:
2893:
2883:
2881:
2873:
2871:
2866:
2865:
2850:Clinical trials
2825:
2780:
2764:
2693:
2614:
2605:Rozanolixizumab
2593:
2587:
2579:
2568:
2381:Lulizumab pegol
2259:
2191:
2125:
1845:
1836:
1806:
1801:
1785:
1740:
1731:
1688:
1680:
1625:
1618:
1588:
1587:
1577:
1575:
1562:
1561:
1546:
1536:
1534:
1529:. 7 July 2015.
1521:
1520:
1516:
1502:
1498:
1484:
1480:
1463:
1443:(4): 460–6.e2.
1430:
1429:
1425:
1415:
1413:
1404:
1403:
1390:
1373:
1366:
1364:
1312:
1311:
1307:
1297:
1295:
1290:. 13 May 2021.
1286:
1285:
1270:
1260:
1258:
1249:
1248:
1244:
1234:
1232:
1219:
1218:
1214:
1202:
1194:
1192:
1176:
1175:
1166:
1156:
1154:
1145:
1144:
1135:
1123:
1115:
1113:
1100:
1099:
1088:
1078:
1076:
1072:
1057:
1049:
1048:
1044:
1032:Wayback Machine
1023:
1019:
1002:
995:
993:
989:
940:
935:
934:
917:
900:
857:
856:
852:
842:
840:
829:"Takhzyro EPAR"
827:
826:
822:
812:
810:
797:
796:
787:
777:
775:
770:. 1 July 2022.
762:
761:
757:
747:
745:
732:
731:
727:
720:
716:
706:
704:
691:
690:
686:
681:
657:priority review
637:clinical trials
633:
585:
568:Injection site
545:
529:
469:in people with
439:
437:
427:
421:
415:
409:
403:
383:
363:
343:
327:
307:
282:
242:
201:
169:
162:
143:
136:
17:
12:
11:
5:
2923:
2921:
2913:
2912:
2907:
2897:
2896:
2892:
2891:
2868:
2867:
2864:
2863:
2862:
2861:
2858:
2847:
2841:
2835:
2834:
2831:
2830:
2827:
2826:
2824:
2823:
2818:
2813:
2808:
2802:
2800:
2793:
2786:
2785:
2782:
2781:
2779:
2778:
2772:
2770:
2766:
2765:
2763:
2762:
2757:
2752:
2747:
2742:
2737:
2732:
2727:
2722:
2717:
2712:
2707:
2701:
2699:
2695:
2694:
2692:
2691:
2686:
2681:
2676:
2671:
2666:
2661:
2656:
2651:
2646:
2641:
2635:
2633:
2626:
2620:
2619:
2616:
2615:
2613:
2612:
2607:
2602:
2596:
2594:
2589:
2588:
2570:
2569:
2563:
2558:
2553:
2548:
2543:
2538:
2533:
2528:
2523:
2518:
2513:
2508:
2503:
2498:
2493:
2488:
2483:
2478:
2473:
2468:
2463:
2458:
2453:
2448:
2443:
2438:
2433:
2428:
2423:
2418:
2413:
2408:
2405:+hyaluronidase
2398:
2393:
2388:
2383:
2378:
2373:
2368:
2363:
2358:
2353:
2348:
2343:
2338:
2333:
2328:
2323:
2318:
2313:
2308:
2303:
2298:
2293:
2288:
2283:
2278:
2269:
2267:
2261:
2260:
2258:
2257:
2252:
2247:
2242:
2237:
2232:
2227:
2222:
2217:
2212:
2207:
2201:
2199:
2193:
2192:
2190:
2189:
2184:
2179:
2174:
2169:
2164:
2159:
2154:
2149:
2144:
2139:
2133:
2131:
2127:
2126:
2124:
2123:
2113:
2112:
2107:
2102:
2092:
2091:
2086:
2081:
2076:
2071:
2061:
2060:
2055:
2050:
2045:
2040:
2035:
2030:
2025:
2020:
2015:
2009:
2004:
1999:
1994:
1989:
1984:
1979:
1974:
1969:
1964:
1959:
1954:
1949:
1944:
1939:
1934:
1929:
1924:
1919:
1914:
1909:
1904:
1899:
1894:
1889:
1884:
1879:
1874:
1862:
1860:
1853:
1847:
1846:
1837:
1835:
1834:
1827:
1820:
1812:
1803:
1802:
1800:
1799:
1793:
1791:
1787:
1786:
1784:
1783:
1778:
1773:
1768:
1763:
1758:
1752:
1750:
1736:Drugs used in
1733:
1732:
1730:
1729:
1724:
1719:
1714:
1709:
1704:
1698:
1696:
1685:Drugs used in
1682:
1681:
1679:
1678:
1673:
1668:
1663:
1653:
1648:
1643:
1637:
1635:
1627:
1626:
1619:
1617:
1616:
1609:
1602:
1594:
1586:
1585:
1544:
1514:
1496:
1478:
1423:
1388:
1305:
1268:
1242:
1212:
1164:
1133:
1086:
1042:
1017:
951:(8): 717–728.
915:
850:
820:
785:
755:
725:
714:
683:
682:
680:
677:
632:
629:
584:
581:
580:
579:
576:
573:
566:
563:
556:
549:adverse events
544:
543:Adverse events
541:
528:
525:
446:
445:
435:
429:
428:
425:
419:
413:
407:
401:
396:
390:
389:
385:
384:
382:
381:
373:
371:
365:
364:
362:
361:
353:
351:
345:
344:
342:
341:
337:
335:
329:
328:
326:
325:
317:
315:
309:
308:
306:
305:
297:
295:
289:
288:
284:
283:
281:
280:
271:
259:
246:
230:
216:
214:
208:
207:
203:
202:
200:
199:
186:
184:
178:
177:
172:
170:administration
164:
163:
161:
160:
158:
148:
146:
138:
137:
135:
134:
116:
114:
108:
107:
100:
90:
89:
86:
82:
81:
78:
72:
71:
67:
66:
61:
55:
54:
49:
43:
42:
41:Whole antibody
39:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
2922:
2911:
2908:
2906:
2903:
2902:
2900:
2890:
2880:
2876:
2859:
2857:
2854:
2853:
2851:
2848:
2845:
2842:
2840:
2837:
2836:
2832:
2822:
2819:
2817:
2814:
2812:
2809:
2807:
2804:
2803:
2801:
2797:
2794:
2792:
2789:Inflammatory
2787:
2777:
2774:
2773:
2771:
2767:
2761:
2760:Tildrakizumab
2758:
2756:
2753:
2751:
2748:
2746:
2743:
2741:
2738:
2736:
2733:
2731:
2728:
2726:
2723:
2721:
2718:
2716:
2713:
2711:
2708:
2706:
2703:
2702:
2700:
2696:
2690:
2687:
2685:
2682:
2680:
2677:
2675:
2672:
2670:
2667:
2665:
2662:
2660:
2657:
2655:
2652:
2650:
2647:
2645:
2642:
2640:
2637:
2636:
2634:
2630:
2627:
2625:
2621:
2611:
2608:
2606:
2603:
2601:
2598:
2597:
2595:
2590:
2586:
2585:
2582:
2578:
2574:
2567:
2564:
2562:
2561:Vobarilizumab
2559:
2557:
2554:
2552:
2549:
2547:
2544:
2542:
2539:
2537:
2534:
2532:
2529:
2527:
2524:
2522:
2519:
2517:
2514:
2512:
2509:
2507:
2506:Spartalizumab
2504:
2502:
2499:
2497:
2494:
2492:
2489:
2487:
2484:
2482:
2479:
2477:
2474:
2472:
2469:
2467:
2464:
2462:
2459:
2457:
2454:
2452:
2449:
2447:
2444:
2442:
2439:
2437:
2434:
2432:
2431:Pembrolizumab
2429:
2427:
2424:
2422:
2419:
2417:
2414:
2412:
2409:
2406:
2402:
2399:
2397:
2394:
2392:
2391:Mogamulizumab
2389:
2387:
2384:
2382:
2379:
2377:
2374:
2372:
2369:
2367:
2364:
2362:
2359:
2357:
2354:
2352:
2349:
2347:
2344:
2342:
2339:
2337:
2334:
2332:
2329:
2327:
2324:
2322:
2319:
2317:
2314:
2312:
2311:Crizanlizumab
2309:
2307:
2304:
2302:
2299:
2297:
2294:
2292:
2289:
2287:
2284:
2282:
2279:
2277:
2274:
2271:
2270:
2268:
2266:
2262:
2256:
2253:
2251:
2248:
2246:
2243:
2241:
2238:
2236:
2233:
2231:
2228:
2226:
2223:
2221:
2218:
2216:
2213:
2211:
2208:
2206:
2205:Andecaliximab
2203:
2202:
2200:
2198:
2194:
2188:
2185:
2183:
2180:
2178:
2175:
2173:
2170:
2168:
2165:
2163:
2160:
2158:
2155:
2153:
2150:
2148:
2145:
2143:
2140:
2138:
2135:
2134:
2132:
2128:
2122:
2118:
2115:
2114:
2111:
2108:
2106:
2103:
2101:
2097:
2094:
2093:
2090:
2087:
2085:
2082:
2080:
2077:
2075:
2072:
2070:
2066:
2063:
2062:
2059:
2056:
2054:
2051:
2049:
2046:
2044:
2041:
2039:
2036:
2034:
2031:
2029:
2026:
2024:
2021:
2019:
2016:
2013:
2010:
2008:
2005:
2003:
2000:
1998:
1995:
1993:
1990:
1988:
1985:
1983:
1980:
1978:
1975:
1973:
1970:
1968:
1965:
1963:
1960:
1958:
1955:
1953:
1950:
1948:
1945:
1943:
1940:
1938:
1935:
1933:
1930:
1928:
1925:
1923:
1920:
1918:
1915:
1913:
1910:
1908:
1905:
1903:
1900:
1898:
1895:
1893:
1890:
1888:
1885:
1883:
1880:
1878:
1875:
1873:
1869:
1868:
1864:
1863:
1861:
1857:
1854:
1852:
1851:Immune system
1848:
1844:
1843:immune system
1840:
1833:
1828:
1826:
1821:
1819:
1814:
1813:
1810:
1798:
1795:
1794:
1792:
1788:
1782:
1779:
1777:
1774:
1772:
1769:
1767:
1764:
1762:
1761:Crizanlizumab
1759:
1757:
1754:
1753:
1751:
1748:
1744:
1739:
1734:
1728:
1725:
1723:
1720:
1718:
1715:
1713:
1712:Conestat alfa
1710:
1708:
1705:
1703:
1700:
1699:
1697:
1694:
1690:
1683:
1677:
1674:
1672:
1671:Streptokinase
1669:
1667:
1666:Hyaluronidase
1664:
1661:
1657:
1654:
1652:
1649:
1647:
1644:
1642:
1639:
1638:
1636:
1633:
1628:
1623:
1615:
1610:
1608:
1603:
1601:
1596:
1595:
1592:
1573:
1569:
1565:
1559:
1557:
1555:
1553:
1551:
1549:
1545:
1532:
1528:
1524:
1518:
1515:
1512:
1508:
1507:
1500:
1497:
1494:
1490:
1489:
1482:
1479:
1474:
1468:
1460:
1456:
1451:
1446:
1442:
1438:
1434:
1427:
1424:
1411:
1407:
1401:
1399:
1397:
1395:
1393:
1389:
1384:
1378:
1362:
1358:
1354:
1350:
1346:
1341:
1336:
1332:
1328:
1324:
1320:
1316:
1309:
1306:
1293:
1289:
1283:
1281:
1279:
1277:
1275:
1273:
1269:
1256:
1252:
1246:
1243:
1230:
1226:
1222:
1216:
1213:
1209:
1208:public domain
1190:
1186:
1185:
1179:
1173:
1171:
1169:
1165:
1152:
1148:
1142:
1140:
1138:
1134:
1130:
1129:public domain
1111:
1107:
1103:
1097:
1095:
1093:
1091:
1087:
1071:
1067:
1063:
1056:
1052:
1046:
1043:
1039:
1038:
1033:
1029:
1026:
1021:
1018:
1013:
1007:
988:
984:
980:
976:
972:
967:
962:
958:
954:
950:
946:
939:
932:
930:
928:
926:
924:
922:
920:
916:
911:
905:
897:
893:
888:
883:
878:
873:
869:
865:
861:
854:
851:
838:
834:
830:
824:
821:
808:
804:
800:
794:
792:
790:
786:
773:
769:
765:
759:
756:
743:
739:
738:Health Canada
735:
729:
726:
723:
718:
715:
702:
698:
694:
688:
685:
678:
676:
672:
670:
666:
662:
658:
654:
650:
646:
642:
638:
630:
628:
626:
622:
617:
613:
608:
606:
602:
598:
594:
590:
582:
577:
574:
571:
567:
564:
561:
557:
554:
553:
552:
550:
542:
540:
538:
534:
526:
524:
522:
517:
515:
511:
507:
503:
499:
495:
491:
487:
482:
480:
476:
472:
468:
464:
460:
457:, is a human
456:
452:
436:
434:
430:
397:
395:
391:
386:
379:
375:
374:
372:
370:
366:
359:
355:
354:
352:
350:
346:
339:
338:
336:
334:
330:
323:
319:
318:
316:
314:
310:
303:
299:
298:
296:
294:
290:
285:
279: Rx-only
272:
270:
260:
257:
247:
240:
231:
228:
218:
217:
215:
213:
209:
204:
196:
191:
188:
187:
185:
183:
179:
176:
173:
171:
165:
159:
150:
149:
147:
145:
139:
132:
127:
118:
117:
115:
113:
109:
105:
101:
99:
95:
91:
87:
83:
79:
77:
73:
70:Clinical data
68:
65:
62:
60:
56:
53:
50:
48:
44:
40:
38:
34:
31:
27:
19:
2910:Orphan drugs
2750:Risankizumab
2735:Lebrikizumab
2715:Clazakizumab
2705:Anrukinzumab
2684:Tralokinumab
2600:Otelixizumab
2580:
2572:
2571:
2541:Tregalizumab
2526:Tislelizumab
2496:Satralizumab
2476:Rontalizumab
2471:Retifanlimab
2446:Plozalizumab
2426:Pateclizumab
2421:Pascolizumab
2416:Ozoralizumab
2366:Lampalizumab
2356:Inebilizumab
2346:Fontolizumab
2296:Camrelizumab
2291:Benralizumab
2286:Atezolizumab
2272:
2215:Clenoliximab
2116:
2100:Bertilimumab
2095:
2084:Tremelimumab
2064:
1987:Mavrilimumab
1977:Lirentelimab
1972:Lerdelimumab
1961:
1947:Fresolimumab
1887:Atorolimumab
1865:
1726:
1707:C1-inhibitor
1702:Berotralstat
1656:Fibrinolysin
1646:Chymotrypsin
1576:. Retrieved
1568:Adis Insight
1567:
1535:. Retrieved
1526:
1517:
1504:
1499:
1486:
1481:
1467:cite journal
1440:
1436:
1426:
1414:. Retrieved
1377:cite journal
1365:. Retrieved
1322:
1318:
1308:
1296:. Retrieved
1259:. Retrieved
1245:
1233:. Retrieved
1215:
1193:. Retrieved
1181:
1155:. Retrieved
1114:. Retrieved
1077:. Retrieved
1065:
1061:
1045:
1035:
1020:
1006:cite journal
994:. Retrieved
948:
944:
904:cite journal
867:
863:
853:
841:. Retrieved
832:
823:
811:. Retrieved
802:
776:. Retrieved
767:
758:
746:. Retrieved
737:
728:
717:
705:. Retrieved
696:
687:
673:
634:
623:, increased
621:vasodilation
616:C1 inhibitor
612:C1 inhibitor
609:
586:
546:
530:
527:Medical uses
518:
483:
454:
450:
449:
302:1426055-14-2
212:Legal status
206:Legal status
175:Subcutaneous
112:License data
18:
2846:from market
2816:Lemalesomab
2811:Fanolesomab
2806:Besilesomab
2745:Perakizumab
2730:Mirikizumab
2720:Gevokizumab
2710:Bimekizumab
2689:Ustekinumab
2674:Secukinumab
2659:Fezakinumab
2654:Canakinumab
2649:Briakinumab
2624:Interleukin
2577:Dostarlimab
2556:Visilizumab
2551:Vedolizumab
2546:Vatelizumab
2536:Toralizumab
2531:Tocilizumab
2516:Teclistamab
2491:Samalizumab
2481:Rovelizumab
2461:Ravulizumab
2441:Pidilizumab
2436:Pexelizumab
2401:Ocrelizumab
2396:Natalizumab
2386:Mepolizumab
2376:Ligelizumab
2371:Letolizumab
2341:Etrolizumab
2331:Epratuzumab
2301:Cedelizumab
2255:Vapaliximab
2250:Teneliximab
2240:Lumiliximab
2225:Gomiliximab
2210:Basiliximab
2182:Vepalimomab
2167:Nerelimomab
2152:Gavilimomab
2147:Faralimomab
2142:Elsilimomab
2117:Combination
2110:Zanolimumab
2105:Ontamalimab
2053:Ulocuplumab
2048:Tezepelumab
2038:Sifalimumab
2018:Pamrevlumab
1997:Morolimumab
1992:Metelimumab
1962:Lanadelumab
1897:Avdoralimab
1882:Anifrolumab
1727:Lanadelumab
1717:Ecallantide
1506:NCT02093923
1488:NCT01923207
1261:10 February
1235:10 February
1195:10 February
996:2 September
966:2434/550555
707:4 September
665:orphan drug
635:In phase I
605:vasodilator
603:, a potent
451:Lanadelumab
444: g·mol
287:Identifiers
131:Lanadelumab
85:Other names
76:Trade names
23:Lanadelumab
2899:Categories
2776:Lokivetmab
2769:Veterinary
2755:Spesolimab
2740:Olokizumab
2725:Ixekizumab
2669:Guselkumab
2664:Fletikumab
2644:Brazikumab
2639:Bermekimab
2610:Sutimlimab
2584:Ibalizumab
2521:Teplizumab
2501:Siplizumab
2486:Ruplizumab
2466:Reslizumab
2456:Quilizumab
2411:Omalizumab
2361:Itolizumab
2351:Frexalimab
2326:Efalizumab
2321:Eculizumab
2316:Daclizumab
2281:Aselizumab
2276:Apolizumab
2245:Priliximab
2230:Infliximab
2172:Odulimomab
2162:Maslimomab
2157:Inolimomab
2137:Afelimomab
2074:Durvalumab
2069:Ipilimumab
2058:Varlilumab
2028:Relatlimab
2023:Placulumab
1967:Lenzilumab
1942:Emapalumab
1927:Cemiplimab
1912:Brodalumab
1907:Bleselumab
1877:Adalimumab
1689:angioedema
1687:hereditary
679:References
649:angioedema
601:bradykinin
589:kallikrein
467:angioedema
463:kallikrein
433:Molar mass
358:2372V1TKXK
333:ChemSpider
293:CAS Number
245:Schedule D
64:Kallikrein
2856:Phase III
2844:Withdrawn
2821:Sulesomab
2698:Humanized
2679:Sirukumab
2511:Talizumab
2336:Erlizumab
2265:Humanized
2235:Keliximab
2220:Galiximab
2079:Nivolumab
2043:Tabalumab
2033:Sarilumab
2007:Oleclumab
2002:Namilumab
1982:Lirilumab
1957:Ianalumab
1952:Golimumab
1937:Eldelumab
1932:Dupilumab
1902:Belimumab
1872:Abrilumab
1781:Voxelotor
1776:Mitapivat
1722:Icatibant
1641:Bromelain
1630:Enzymes (
1079:5 October
697:Drugs.com
641:kininogen
597:kininogen
539:attacks.
533:indicated
510:dizziness
168:Routes of
142:Pregnancy
104:Monograph
98:Drugs.com
2889:Medicine
2197:Chimeric
2089:Urelumab
2012:Oxelumab
1922:Carlumab
1892:Avelumab
1841:for the
1578:24 March
1572:Archived
1537:24 March
1531:Archived
1459:24980392
1410:Archived
1367:15 March
1361:Archived
1357:53757796
1349:30480729
1298:24 March
1292:Archived
1255:Archived
1229:Archived
1189:Archived
1151:Archived
1116:15 March
1110:Archived
1070:Archived
1053:(2015).
1028:Archived
987:Archived
983:54486011
975:28225674
896:24970892
837:Archived
807:Archived
803:DailyMed
772:Archived
742:Archived
701:Archived
593:protease
570:erythema
514:diarrhea
498:headache
490:bruising
455:Takhzyro
313:DrugBank
182:ATC code
157: B1
144:category
126:DailyMed
80:Takhzyro
2791:lesions
2566:TGN1412
2451:PRO 140
1676:Trypsin
1340:6583584
1223:. U.S.
1104:. U.S.
887:4156074
631:History
519:The US
506:myalgia
394:Formula
322:DB14597
241: /
237::
198:)
192: (
190:B06AC05
128::
2875:Portal
2839:WHO-EM
2581:Other:
1790:Others
1457:
1416:1 July
1355:
1347:
1337:
1157:1 July
981:
973:
894:
884:
843:30 May
813:30 May
778:1 July
748:29 May
663:, and
558:Viral
512:, and
378:D11094
269:℞-only
267:
254:
243:
239:℞-only
225:
124:
59:Target
47:Source
2799:Mouse
2632:Human
2130:Mouse
2096:Other
1859:Human
1797:Hemin
1747:B06AX
1693:B06AC
1632:B06AA
1353:S2CID
1182:U.S.
1073:(PDF)
1068:(4).
1058:(PDF)
990:(PDF)
979:S2CID
941:(PDF)
768:(emc)
669:Shire
408:10016
52:Human
1741:and
1580:2017
1539:2017
1473:link
1455:PMID
1418:2022
1383:link
1369:2021
1345:PMID
1319:JAMA
1300:2017
1263:2023
1237:2023
1197:2023
1159:2022
1118:2021
1081:2020
1012:link
998:2019
971:PMID
910:link
892:PMID
845:2022
815:2022
780:2022
750:2022
709:2020
502:rash
420:2012
414:1728
402:6468
369:KEGG
349:UNII
340:none
94:AHFS
37:Type
1622:B06
1445:doi
1441:113
1335:PMC
1327:doi
1323:320
961:hdl
953:doi
949:376
882:PMC
872:doi
868:289
442:.18
440:684
438:145
256:POM
195:WHO
2901::
2852::
2575::
2119::
2098::
2067::
1870::
1566:.
1547:^
1525:.
1469:}}
1465:{{
1453:.
1439:.
1435:.
1408:.
1391:^
1379:}}
1375:{{
1359:.
1351:.
1343:.
1333:.
1321:.
1317:.
1271:^
1180:.
1167:^
1149:.
1136:^
1089:^
1066:29
1064:.
1060:.
1034:,
1008:}}
1004:{{
985:.
977:.
969:.
959:.
947:.
943:.
918:^
906:}}
902:{{
890:.
880:.
866:.
862:.
831:.
801:.
788:^
766:.
736:.
695:.
671:.
659:,
607:.
516:.
508:,
504:,
500:,
496:,
492:,
426:47
275:EU
263:US
250:UK
234:CA
227:S4
221:AU
153:AU
121:US
2877::
2407:)
2403:(
2014:§
1831:e
1824:t
1817:v
1749:)
1745:(
1695:)
1691:(
1662:)
1658:(
1634:)
1624:)
1613:e
1606:t
1599:v
1582:.
1541:.
1475:)
1461:.
1447::
1420:.
1385:)
1371:.
1329::
1302:.
1265:.
1239:.
1210:.
1199:.
1161:.
1131:.
1120:.
1083:.
1040:.
1014:)
1000:.
963::
955::
912:)
898:.
874::
847:.
817:.
782:.
752:.
711:.
423:S
417:O
411:N
405:H
399:C
277::
265::
252::
223::
155::
96:/
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.